Scenarios that move SNY
Sanofi - American Depositary Shares
Scenarios that move SNY: 17 analyses, 6 positive, 11 negative.
- · argenx meets primary endpoint in Phase II celiac disease study — ▲ · impact +25 · confidence low · horizon quarters
- · ◇ What if… Édouard Philippe wins France’s 2027 presidential election — ▲ · impact +56 · confidence medium · horizon weeks
- · HALO wins court order blocking Merck's European Keytruda SC — ▼ · impact -10 · confidence low · horizon quarters
- · Bavarian Nordic raises 2026 outlook after strong Travel Health results — ▲ · impact +40 · confidence low · horizon quarters
- · Vaxcyte prices concurrent stock, warrant and convertible note offerings — ▼ · impact -15 · confidence low · horizon quarters
- · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▼ · impact -15 · confidence low · horizon quarters
- · United Therapeutics stock rises 12.6% in trading — ▼ · impact -28 · confidence low · horizon quarters
- · DBV Technologies files FDA BLA for VIASKIN Peanut patch — ▼ · impact -8 · confidence medium · horizon quarters
- · Mirum's Brelovitug meets goal in Phase III AZURE-1 study — ▼ · impact -24 · confidence low · horizon quarters
- · ◇ What if… Jean-Luc Mélenchon wins France’s 2027 presidential election — ▼ · impact -55 · confidence high · horizon quarters
- · Beta Bionics stock plunges 37% after safety issues emerge — ▲ · impact +5 · confidence low · horizon quarters
- · Pharma stock soars 150% after injectables deal with Novo — ▼ · impact -45 · confidence low · horizon weeks
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▼ · impact -7 · confidence low · horizon quarters
- · Sion cuts workforce nearly half after CF study failure — ▲ · impact +30 · confidence low · horizon quarters
- · Ascendis announces planned $400 million share repurchase program — ▼ · impact -25 · confidence low · horizon quarters
- · ◇ What if… Marine Le Pen wins France’s 2027 presidential election — ▼ · impact -54 · confidence medium · horizon weeks
- · Amgen shares fall after Novartis' Pelacarsen misses Phase III goal — ▲ · impact +25 · confidence low · horizon quarters